<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Novocure Ltd — News on 6ix</title>
<link>https://6ix.com/company/novocure-ltd</link>
<description>Latest news and press releases for Novocure Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 01 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/novocure-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a42778dffbe2df10a88a.webp</url>
<title>Novocure Ltd</title>
<link>https://6ix.com/company/novocure-ltd</link>
</image>
<item>
<title>Novocure to Report First Quarter 2026 Financial Results</title>
<link>https://6ix.com/company/novocure-ltd/news/novocure-to-report-first-quarter-2026-financial-results-5</link>
<guid isPermaLink="true">https://6ix.com/company/novocure-ltd/news/novocure-to-report-first-quarter-2026-financial-results-5</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2026 on April 30, 2026, before the U.S.</description>
</item>
<item>
<title>Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer</title>
<link>https://6ix.com/company/novocure-ltd/news/novocure-announces-positive-topline-results-from-phase-2-panova-4-clinical-trial-of-tumor-treating-fields-ttfields-therapy-for-metastatic-pancreatic-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/novocure-ltd/news/novocure-announces-positive-topline-results-from-phase-2-panova-4-clinical-trial-of-tumor-treating-fields-ttfields-therapy-for-metastatic-pancreatic-cancer</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced positive results today from the Phase 2 PANOVA-4 trial of Tumor Treating Fields</description>
</item>
<item>
<title>Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer</title>
<link>https://6ix.com/company/novocure-ltd/news/novocure-announces-optune-luar-receives-reimbursement-approval-in-japan-for-the-treatment-of-non-small-cell-lung-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/novocure-ltd/news/novocure-announces-optune-luar-receives-reimbursement-approval-in-japan-for-the-treatment-of-non-small-cell-lung-cancer</guid>
<pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
<description>Novocure to launch Optune Lua in Japan with national reimbursement coverage BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that</description>
</item>
<item>
<title>Novocure to Participate in 2026 Leerink Global Healthcare Conference</title>
<link>https://6ix.com/company/novocure-ltd/news/novocure-to-participate-in-2026-leerink-global-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/novocure-ltd/news/novocure-to-participate-in-2026-leerink-global-healthcare-conference</guid>
<pubDate>Fri, 27 Feb 2026 21:30:00 GMT</pubDate>
<description>BAAR, Switzerland, February 27, 2026--Novocure to Participate in 2026 Leerink Global Healthcare Conference</description>
</item>
<item>
<title>Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update</title>
<link>https://6ix.com/company/novocure-ltd/news/novocure-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-company-update</link>
<guid isPermaLink="true">https://6ix.com/company/novocure-ltd/news/novocure-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-company-update</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>Full year 2025 net revenues of $655 million and fourth quarter net revenues of $174 million Optune Pax® approved by the U.S. FDA for the treatment of locally</description>
</item>
<item>
<title>Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)</title>
<link>https://6ix.com/company/novocure-ltd/news/tumor-treating-fields-ttfields-therapy-to-be-covered-for-patients-with-newly-diagnosed-glioblastoma-through-british-columbia-cancer-bc-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/novocure-ltd/news/tumor-treating-fields-ttfields-therapy-to-be-covered-for-patients-with-newly-diagnosed-glioblastoma-through-british-columbia-cancer-bc-cancer</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>British Columbia becomes first Canadian province to provide coverage for TTFields therapy for eligible glioblastoma patients BAAR, Switzerland--(BUSINESS</description>
</item>
<item>
<title>U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer</title>
<link>https://6ix.com/company/novocure-ltd/news/u-fda-approves-novocure-optune-225400947</link>
<guid isPermaLink="true">https://6ix.com/company/novocure-ltd/news/u-fda-approves-novocure-optune-225400947</guid>
<pubDate>Wed, 11 Feb 2026 22:54:00 GMT</pubDate>
<description>BAAR, Switzerland, February 11, 2026--Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved Optune Pax® for the treatment of adult patients with locally advanced pancreatic cancer concomitant with gemcitabine and nab-paclitaxel.</description>
</item>
<item>
<title>Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update</title>
<link>https://6ix.com/company/novocure-ltd/news/novocure-announces-preliminary-full-year-and-fourth-quarter-2025-performance-and</link>
<guid isPermaLink="true">https://6ix.com/company/novocure-ltd/news/novocure-announces-preliminary-full-year-and-fourth-quarter-2025-performance-and</guid>
<pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
<description>Preliminary full year 2025 net revenues of $655 million and fourth quarter net revenues of $174 million Novocure to present at the 44th Annual J.P. Morgan</description>
</item>
<item>
<title>Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/novocure-ltd/news/novocure-present-44th-annual-jp-morgan-healthcare-conference-2025-12-22</link>
<guid isPermaLink="true">https://6ix.com/company/novocure-ltd/news/novocure-present-44th-annual-jp-morgan-healthcare-conference-2025-12-22</guid>
<pubDate>Mon, 22 Dec 2025 05:00:00 GMT</pubDate>
<description>BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that management will participate in the 44th Annual J.P. Morgan Healthcare</description>
</item>
<item>
<title>Novocure Appoints Company President Frank Leonard as Chief Executive Officer</title>
<link>https://6ix.com/company/novocure-ltd/news/novocure-appoints-company-president-frank-leonard-chief-executive-officer-2025-12-01</link>
<guid isPermaLink="true">https://6ix.com/company/novocure-ltd/news/novocure-appoints-company-president-frank-leonard-chief-executive-officer-2025-12-01</guid>
<pubDate>Mon, 01 Dec 2025 05:00:00 GMT</pubDate>
<description>BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today announced the appointment of Frank Leonard as Chief Executive Officer (CEO), effective</description>
</item>
<item>
<title>Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference</title>
<link>https://6ix.com/company/novocure-ltd/news/novocure-participate-37th-annual-piper-sandler-healthcare-conference-2025-11-26</link>
<guid isPermaLink="true">https://6ix.com/company/novocure-ltd/news/novocure-participate-37th-annual-piper-sandler-healthcare-conference-2025-11-26</guid>
<pubDate>Wed, 26 Nov 2025 05:00:00 GMT</pubDate>
<description>BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that management will participate in the 37th Annual Piper Sandler Healthcare</description>
</item>
<item>
<title>Novocure to Participate in 2025 Jefferies Global Healthcare Conference</title>
<link>https://6ix.com/company/novocure-ltd/news/novocure-participate-2025-jefferies-global-healthcare-conference-2025-11-12</link>
<guid isPermaLink="true">https://6ix.com/company/novocure-ltd/news/novocure-participate-2025-jefferies-global-healthcare-conference-2025-11-12</guid>
<pubDate>Wed, 12 Nov 2025 05:00:00 GMT</pubDate>
<description>BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that management will participate in the Jefferies Global Healthcare Conference</description>
</item>
<item>
<title>Novocure Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/novocure-ltd/news/novocure-reports-third-quarter-2025-financial-results-2025-10-30</link>
<guid isPermaLink="true">https://6ix.com/company/novocure-ltd/news/novocure-reports-third-quarter-2025-financial-results-2025-10-30</guid>
<pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
<description>Quarterly net revenues of $167 million, up 8% year-over-year, with 4,416 active patients on therapy as of September 30, 2025 Premarket approval application</description>
</item>
<item>
<title>Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress</title>
<link>https://6ix.com/company/novocure-ltd/news/novocure-present-new-research-tumor-treating-fields-ttfields-therapy-european</link>
<guid isPermaLink="true">https://6ix.com/company/novocure-ltd/news/novocure-present-new-research-tumor-treating-fields-ttfields-therapy-european</guid>
<pubDate>Wed, 15 Oct 2025 04:00:00 GMT</pubDate>
<description>BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that it will present data at two upcoming oncology congresses, the 2025 European</description>
</item>
<item>
<title>Novocure to Report Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/novocure-ltd/news/novocure-report-third-quarter-2025-financial-results-2025-10-01</link>
<guid isPermaLink="true">https://6ix.com/company/novocure-ltd/news/novocure-report-third-quarter-2025-financial-results-2025-10-01</guid>
<pubDate>Wed, 01 Oct 2025 04:00:00 GMT</pubDate>
<description>BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) will report financial results for the third quarter 2025 on October 30, 2025, before the U.S.</description>
</item>
<item>
<title>Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting</title>
<link>https://6ix.com/company/novocure-ltd/news/novocure-present-final-results-pivotal-phase-3-metis-trial-its-tumor-treating-fields</link>
<guid isPermaLink="true">https://6ix.com/company/novocure-ltd/news/novocure-present-final-results-pivotal-phase-3-metis-trial-its-tumor-treating-fields</guid>
<pubDate>Mon, 29 Sep 2025 04:00:00 GMT</pubDate>
<description>METIS trial achieved its primary endpoint, showing a statistically significant delay in time to intracranial progression in patients receiving TTFields</description>
</item>
<item>
<title>Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)</title>
<link>https://6ix.com/company/novocure-ltd/news/novocures-optune-luar-receives-approval-japan-treatment-unresectable-advanced</link>
<guid isPermaLink="true">https://6ix.com/company/novocure-ltd/news/novocures-optune-luar-receives-approval-japan-treatment-unresectable-advanced</guid>
<pubDate>Mon, 15 Sep 2025 04:00:00 GMT</pubDate>
<description>Optune Lua is now approved for use concurrently with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced/recurrent NSCLC who progressed on or</description>
</item>
<item>
<title>Novocure Announces Upcoming Investor Events</title>
<link>https://6ix.com/company/novocure-ltd/news/novocure-announces-upcoming-investor-events-2025-08-28</link>
<guid isPermaLink="true">https://6ix.com/company/novocure-ltd/news/novocure-announces-upcoming-investor-events-2025-08-28</guid>
<pubDate>Thu, 28 Aug 2025 04:00:00 GMT</pubDate>
<description>BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that management will participate in three upcoming investor events. 2025 Wells</description>
</item>
<item>
<title>Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain</title>
<link>https://6ix.com/company/novocure-ltd/news/novocure-announces-coverage-tumor-treating-fields-ttfields-therapy-patients-newly</link>
<guid isPermaLink="true">https://6ix.com/company/novocure-ltd/news/novocure-announces-coverage-tumor-treating-fields-ttfields-therapy-patients-newly</guid>
<pubDate>Mon, 25 Aug 2025 04:00:00 GMT</pubDate>
<description>Eligible patients can receive TTFields therapy through the Spanish National Health System BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR)</description>
</item>
<item>
<title>Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer</title>
<link>https://6ix.com/company/novocure-ltd/news/novocure-submits-premarket-approval-application-fda-tumor-treating-fields-therapy</link>
<guid isPermaLink="true">https://6ix.com/company/novocure-ltd/news/novocure-submits-premarket-approval-application-fda-tumor-treating-fields-therapy</guid>
<pubDate>Wed, 20 Aug 2025 04:00:00 GMT</pubDate>
<description>BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today announced it submitted a premarket approval (PMA) application to the U.S. Food and Drug</description>
</item>
</channel>
</rss>